Company intelligence / Profile preview

Spiral Networks

South San Francisco, California, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

SPT‑2101, a long‑acting dexamethasone formulation delivered via the MICS™ platform for Ménière’s disease, has completed a Phase 1b/2a clinical trial. Data presented in late 2024 showed substantial reduction in definitive vertigo days and improved quality of life for patients with Ménière’s disease.

Therapeutic areas: Neurology
Modalities: Small moleculeSustained-release formulation delivery systemSteroid
Industry: Biotech

Beyond the preview

Go deeper on Spiral Networks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spiral Networks.

Explore the full profile